<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Naidu SK</submitter><funding>Louisiana Board of Regents</funding><funding>NIGMS NIH HHS</funding><pagination>e0228252</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7004361</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(2)</volume><pubmed_abstract>Herpes simplex virus type-1 (HSV-1) can cause severe ocular infection and blindness. We have previously shown that the HSV-1 VC2 vaccine strain is protective in mice and guinea pigs against genital herpes infection following vaginal challenge with HSV-1 or HSV-2. In this study, we evaluated the efficacy of VC2 intramuscular vaccination in mice against herpetic keratitis following ocular challenge with lethal human clinical strain HSV-1(McKrae). VC2 vaccination in mice produced superior protection and morbidity control in comparison to its parental strain HSV-1(F). Specifically, after HSV-1(McKrae) ocular challenge, all VC2 vaccinated- mice survived, while 30% of the HSV-1(F)- vaccinated and 100% of the mock-vaccinated mice died post challenge. VC2-vaccinated mice did not exhibit any sympto</pubmed_abstract><journal>PloS one</journal><pubmed_title>Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis.</pubmed_title><pmcid>PMC7004361</pmcid><funding_grant_id>P20 GM103424</funding_grant_id><funding_grant_id>GBI</funding_grant_id><pubmed_authors>Kousoulas KG</pubmed_authors><pubmed_authors>Jambunathan N</pubmed_authors><pubmed_authors>Nabi R</pubmed_authors><pubmed_authors>Langohr I</pubmed_authors><pubmed_authors>Cheemarla NR</pubmed_authors><pubmed_authors>Rider PJ</pubmed_authors><pubmed_authors>Stanfield BA</pubmed_authors><pubmed_authors>Naidu SK</pubmed_authors><pubmed_authors>Carter R</pubmed_authors><pubmed_authors>Del Piero F</pubmed_authors><pubmed_authors>Chouljenko VN</pubmed_authors></additional><is_claimable>false</is_claimable><name>Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis.</name><description>Herpes simplex virus type-1 (HSV-1) can cause severe ocular infection and blindness. We have previously shown that the HSV-1 VC2 vaccine strain is protective in mice and guinea pigs against genital herpes infection following vaginal challenge with HSV-1 or HSV-2. In this study, we evaluated the efficacy of VC2 intramuscular vaccination in mice against herpetic keratitis following ocular challenge with lethal human clinical strain HSV-1(McKrae). VC2 vaccination in mice produced superior protection and morbidity control in comparison to its parental strain HSV-1(F). Specifically, after HSV-1(McKrae) ocular challenge, all VC2 vaccinated- mice survived, while 30% of the HSV-1(F)- vaccinated and 100% of the mock-vaccinated mice died post challenge. VC2-vaccinated mice did not exhibit any sympto</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020</publication><modification>2025-04-19T01:59:05.709Z</modification><creation>2020-05-22T10:27:21Z</creation></dates><accession>S-EPMC7004361</accession><cross_references><pubmed>32027675</pubmed><doi>10.1371/journal.pone.0228252</doi></cross_references></HashMap>